BRIEF-Teva announces data from second phase 3 study of SD-809
September 22, 2016 at 08:14 AM EDT
* Teva announces positive top-line data from second phase 3 study of SD-809 in Tardive Dyskinesia (TD)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.